Author

C. P. Miller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Johnson· 1 shared A. M. H. Towlerton· 1 shared A. Reynolds· 1 shared C. Lu· 1 shared D. Bates· 1 shared D. Dunn· 1 shared D. G. Coffey· 1 shared D. M. Koelle· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Johnson

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

T-cells specific for KSHV and HIV migrate to Kaposi sarcoma tumors and persist over time

S. Ravishankar, A. M. H. Towlerton, I. L. Tiamiyu, P. Mooka, J. Nankoma, J. Kafeero, D. Mubiru, S. Sekitene, L. D. Aicher, C. P. Miller, D. G. Coffey, L. Okoche, P. Atwinirembabazi, J. Okonye, J. White, , E. H. Warren

The paper identifies KSHV- and HIV-specific T-cells in KS tumors and shows they persist over time and coexist with immunosuppressive macrophages.

bioRxiv · Feb 6, 2024 · PreprintImmunology

VHL Synthetic Lethality Signatures Uncovered by Genotype-specific CRISPR-Cas9 Screens

N. Sun, S. Petiwala, C. Lu, J. E. Hutti, M. Hu, M. Hu, M. H. Domanus, D. Mitra, S. N. Addo, C. P. Miller, N. Chung

The paper uses CRISPR-Cas9 screens in isogenic ccRCC cell lines to identify synthetic lethal partners of VHL, revealing new therapeutic targets for renal cell carcinoma.

bioRxiv · Mar 26, 2019Cancer Biology

Cryptic Promoter Activation Drives POU5F1 (OCT4) Expression in Renal Cell Carcinoma

K. T. Siebenthall, C. P. Miller, J. D. Vierstra, J. Mathieu, M. Tretiakova, A. Reynolds, R. Sandstrom, E. Rynes, S. J. Neph, E. Haugen, A. Johnson, J. Nelson, D. Bates, M. Diegel, D. Dunn, , S. Akilesh

The paper identifies a HIF-pathway-responsive cryptic promoter driving POU5F1 expression in RCC, linked to poor patient outcomes.

bioRxiv · Jul 27, 2018Cancer Biology